SINGAPORE, May 28, 2014 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced that Mr. Jose ("Pepe") Calle Gordo has been appointed the Company's new Chief Executive Officer (CEO), with effect from 1st November 2014. Dr. Jack Wang will continue with the company to help the transition and take on a new role of Chief Technology Officer. Meanwhile, Mr. Yoh-Chie Lu, Biosensors' Executive Chairman, will serve as interim CEO during this transitional period.
"Dr. Wang's vision and dedication have played a significant role in our transformation from a small medical device company to an internationally recognized and profitable corporation. We want to thank him for his significant contributions," Mr. Lu commented. "Mr. Calle, with his expertise in the drug eluting stent industry and extensive international experience, will lead the future growth of Biosensors as it evolves from a successful entrepreneurial company to a more diverse and structured international organization. I will work with the rest of the management team as interim CEO to ensure a smooth transition and execute the growth strategies set up by our board."
Mr. Calle had a successful career with over 25 years of broad business and management experience in the medical devices industry, having served in various vice president and managerial roles at Abbott, Guidant and Eli Lilly. He led the global team that developed and commercialized Xience, a family of drug eluting stents (DES) and a market leader for the treatment of coronary artery disease while serving as Vice President and General Manager of the Drug Eluting Stents, Vascular Intervention at Guidant based in Santa Clara, California (US).
As Vice President of Abbott Vascular based in Brussels, he later managed the international operations of Abbott Vascular outside of the U.S. and more recently he led the commercial introduction of bioresorbable vascular scaffolds (ABSORB BVS) and MitraClip, the world's first percutaneous mitral valve repair therapy.
During his earlier years with Guidant and Eli Lilly he contributed in different managerial roles to the commercial and therapy development of the implanted defibrillator and cardiac resynchronization therapy.
"I am delighted to be joining Biosensors as CEO," said Mr. Calle. "With my experience in leading the development and commercial success of innovative new medical products across the globe, I am confident that I can help Biosensors strengthen its position in the worldwide drug eluting stent market, develop innovative technologies to broaden its product portfolio, and steer the Company onto the path of becoming a bigger international player with multiple product platforms."
Media/Investor Relations Contact
Wong Teck Yenn
Director, Investor Relations
Tel: +65-6213-5777
Email: ir@biosensors.com
About Biosensors International Group, Ltd
Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, we were listed on the Mainboard of the Singapore Stock Exchange in 2005.
The Group currently operates through four business units ("BU"): the Cardiovascular BU, composed primarily of the BioMatrix™ family of drug-eluting stents and stent technologies such as BA9; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; the Peripheral Intervention BU, offering solutions for the treatment of patients with peripheral arterial disease; and the Critical Care Products BU.
The Group has operations worldwide and is headquartered in Singapore.
For more information, please visit www.biosensors.com.
Forward-Looking Statements
Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.
